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SUMMARY
Few data are available about progressive multifocal leukoencephalopathy (PML) in patients with acquired immunodeficiency
syndrome (AIDS) from Brazil. The objectives of this study were to describe the main features of patients with PML and estimate
its frequency among AIDS patients with central nervous system (CNS) opportunistic diseases admitted to the Instituto de Infectologia
Emílio Ribas, São Paulo, Brazil, from April 2003 to April 2004. A retrospective and descriptive study was performed. Twelve (6%)
cases of PML were identified among 219 patients with neurological diseases. The median age of patients with PML was 36 years
and nine (75%) were men. Nine (75%) patients were not on antiretroviral therapy at admission. The most common clinical
manifestations were: focal weakness (75%), speech disturbances (58%), visual disturbances (42%), cognitive dysfunction (42%),
and impaired coordination (42%). The median CD4+ T-cell count was 45 cells/µL. Eight (67%) of 12 patients were laboratory-
confirmed with PML and four (33%) were possible cases. Eleven (92%) presented classic PML and only one case had immune
reconstitution inflammatory syndrome (IRIS)-related PML. In four (33%) patients, PML was the first AIDS-defining illness.
During hospitalization, three patients (25%) died as a result of nosocomial pneumonia and nine (75%) were discharged to home.
Cases of PML were only exceeded by cases of cerebral toxoplasmosis, cryptococcal meningoencephalitis, and CNS tuberculosis,
the three more frequent neurologic opportunistic infections in Brazil. The results of this study suggest that PML is not an uncommon
HIV-related neurologic disorder in a referral center in Brazil.
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INTRODUCTION
Progressive multifocal leukoencephalopathy (PML) is a disease of
the central nervous system (CNS) caused by the virus JC and
characterized by lytic infection of the oligodendrocytes and
demyelination10, tipically occuring in the context of severe
immunodepression. After the advent of the HIV epidemic, acquired
immunodeficiency syndrome (AIDS) became the most common
predisposing disorder for PML1. This disease has been diagnosed in up
to 5% of HIV-infected patients in developed countries in the pre highly
active antiretroviral therapy (HAART) era10. However, the incidence of
PML has decreased less dramatically when compared to other CNS
diseases in the HAART era6,21. Interestingly, PML has rarely been reported
in HIV-infected patients from developing countries8,11,12. The objectives
of this study were to describe the clinical and radiological features of
patients with PML and estimate its frequency among AIDS patients with
CNS opportunistic diseases admitted in a referral center in Brazil.
PATIENTS AND METHODS
We performed a retrospective and descriptive study at the Instituto
de Infectologia Emílio Ribas, São Paulo, Brazil, from April 2003 to
April 2004. All adult HIV-infected patients admitted with a defined
diagnosis of a CNS opportunistic disease were included. For this
purpose, the records of the following institutions were revised and
selected for patients with PML: 1) Laboratory and Department of
Neurology at the Instituto de Infectologia Emílio Ribas, and 2)
Laboratory of Virology at the Instituto de Medicina Tropical de São
Paulo. This study was approved by the Institutional Review Board of
the Instituto de Infectologia Emílio Ribas.
The diagnosis of PML was classified as follows: histology-
confirmed PML (clinical and radiological features consistent with PML
associated with histopathological diagnosis); laboratory-confirmed
PML (compatible clinical and radiological features associated with
the presence of JC virus DNA in cerebrospinal fluid -CSF-); and
possible PML (clinical and radiological findings consistent with PML)4.
In addition, PML was classified by classic (PML in the setting of severe
immunodeficiency) and immune reconstitution inflammatory syndrome
(IRIS)-related PML10. Inflammatory PML occurs in the setting of a
recovery of the immune system marked by an increase in CD4+ T -
cell counts and a decrease in HIV plasma viral load10. The criteria for
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cerebral toxoplasmosis, cryptococcal meningoencephalitis, CNS
tuberculosis, CNS cytomegalovirus, and primary CNS lymphoma were
defined according to a recent consensus17. Neurosyphilis was diagnosed
in patients with a reactive Venereal Disease Research Laboratory in
CSF. Trypanosoma cruzi meningoencephalitis diagnosis was based on
the direct identification of T. cruzi in CSF. BK virus
meningoencephalitis was based on clinical and radiological features
of meningoencephalitis associated with a presence of BK virus DNA
in CSF and brain tissue. The polymerase chain reaction (PCR) for JC
virus DNA in CSF samples was performed using primers to amplify
the T-antigen genes (173 bp) from both BK virus and JC virus. The
presence of the JC virus was confirmed by digestion of the PCR product
using BamH1, as previously described7. HIV infection was documented
by HIV-1 antibody enzyme-linked immunosorbent assay and Western
blot analysis.
RESULTS
A total of 219 HIV-infected patients with CNS opportunistic
diseases were included. Twelve (6%) patients presented with PML,
which was the fourth most frequent opportunistic complication after
cerebral toxoplasmosis (n = 110, 50%), cryptococcal
meningoencephalitis (n = 53, 24%), and CNS tuberculosis (n = 32,
15%). Other diagnoses were neurosyphilis (n = 4, 2%), primary CNS
lymphoma (n = 3, 1%), CNS cytomegalovirus (n = 3, 1%), T. cruzi
meningoencephalitis (n = 1, 0.4%), and BK virus meningoencephalitis
(n = 1, 0.4%). The last two cases were previously published13,23.
Of the 12 patients with PML, eight (67%) were laboratory-
confirmed and four (33%) were possible cases. There were no cases
of histology-confirmed PML. Eleven (92%) patients presented with
classic PML and only one case had IRIS-related PML. All patients
were aware of their HIV status at admission. In four (33%) patients,
PML was the first AIDS-defining illness. Nine (75%) patients were
not on antiretroviral therapy at admission and were placed on HAART
within the first two weeks of diagnosis of PML. The median time of
HAART use in the other three patients was two months (range: 1-3
months), and none of them were virologically suppressed at admission
(detection limit of HIV-1 viral load = 400 copies/mL). The median
age of patients with PML was 36 years (range: 25-52 years), and
nine (75%) were men. The most common clinical manifestations were
focal weakness (75%), speech disturbances (58%), visual disturbances
(42%), cognitive dysfunction (42%), and impaired coordination
(42%). Seizures were reported in only one (8%) case. The median of
CD4+ T-cell count was 45 cells/µL (range: 3-210 cells/µL). Brain
computed tomography (CT) imaging showed multiple hypodense
areas in the white matter in nine patients and a single hypodense
area in three patients. Magnetic resonance imaging (MRI) was
performed in seven patients, and in all cases, multiple hyperintense
areas on T2-weighted and fluid attenuated inversion recovery images
were observed in the white matter of the cerebral hemispheres. In
addition, five (42%) of these patients showed lesions in the cerebellum
or brain stem. The single patient with IRIS-related PML presented
with areas of peripheral enhancement with contrast media associated
to discrete mass effect on both CT and MRI. During hospitalization,
three patients (25%) died as a result of nosocomial pneumonia and
nine (75%) were discharged to home.
DISCUSSION
We found that the frequency of PML in this hospital-based study
was 6%, similar to that found in developed countries in the pre-HAART
era. The results of this study suggest that PML is not an uncommon
HIV-related neurological disorder in our setting. Cases of PML were
only exceeded by cases of cerebral toxoplasmosis, cryptococcal
meningoencephalitis, and CNS tuberculosis, the three more frequent
and well described neurological opportunistic infections in most of
developing countries, including Brazil.
All PML patients included in this study were aware of their HIV
status and presented with low CD4+ T cell counts. We have observed
similar profiles in other neurological disorders associated with HIV-1
infection when HAART has not being used24.
Clinical, laboratory and radiological presentation of the present
series of cases was similar to what has been previously described10,19.
Although most of the patients presented with classic PML, and only
one (8%) had IRIS-related PML, a prior study reported this clinical
presentation in 19% of cases3.
There are a few reports of PML in Brazil. Five pathological studies
which examined a total 519 Brazilian HIV-infected patients, 90% of
whom were observed in the pre-HAART era, showed only two cases
of PML (0.4%)2,5,14,20,25. In a clinical study of 172 patients from the
pre-HAART era, only two cases of possible PML were reported (1%)18.
In contrast, a more recent assessment of 194 patients with neurological
diseases during the HAART-era showed seven (4%) cases of possible
PML15. In addition, our group recently reported 27 cases of laboratory-
confirmed PML, and showed that this disease was the most prevalent
disorder among 56 HIV-infected patients with focal brain lesions and
without mass effect7.
The results of the present study suggest that PML might be more
frequently diagnosed in developing countries when modern diagnostic
procedures can be employed. For example, a recent survey in Uganda
found that four (8%) of 50 HIV-infected patients with neurologic
symptoms yielded the presence of JC virus DNA in CSF (C. Pierotti and
P. Cinque, personal communication). Several possible reasons may
explain the low prevalence reported of PML in developing countries22.
First, there may be underdiagnosis or underreporting because of difficult
access to reference centers with experienced clinicians and adequate
diagnostic support, including molecular diagnosis, neuroimaging,
neurosurgery, and low necropsy rates. Second, death may be due to other
causes, such as opportunistic infections that require less
immunosupression than PML and continue to increased morbidity and
mortality, such as pneumonia due to Pneumocystis jiroveci and
tuberculosis. Furthermore, progressive improvement in medical care and
access to health services could explain the prolonged life span in HIV-
infected patients, predisposing to the presence of opportunistic diseases
that require more immunosuppression, such as PML. Third, there may
be possible interactions between JC virus and the different HIV-1 clades.
The low prevalence of PML in geographic areas where the HIV-1 subtype
C predominates, including India and Africa, might involve different
biological interactions between the two virus. Conversely, in Brazil,
similar to United States and Europe, the most prevalent subtype is B,
especially in southeastern Brazil, including São Paulo, Rio de Janeiro
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and Minas Gerais States, from where most PML cases were reported. In
addition, other issues might theoretically be responsible for the low local
prevalence of PML in some areas, such as genomic diversity of JC virus
strains, including the possibility of predominance of low virulent strains
of JC virus16, and host genetic differences.
This study has some limitations, including a relatively low number
of patients from a single referral center. A broader source of patients
may have improved the generalizability of the findings. In this study
only patients with a defined diagnosis of CNS opportunistic diseases
were included. Hence, the frequency of PML might have been
overestimated. In addition, the retrospective nature of this study imposes
several inherent limitations, and an ongoing prospective study might
confirm the findings of this report.
In conclusion, PML appears to be a relevant neurological problem
in a referral hospital in Brazil and possibly in other centers from
developing countries. In this regard, epidemiological prospective studies
based on the use of standardized diagnostic protocols are warranted to
define the true prevalence of PML in this setting.
RESUMO
Leucoencefalopatia multifocal progressiva em pacientes com
aids: estudo retrospectivo em um centro de referência de São
Paulo, Brasil
Existe informação limitada sobre a presença da leucoencefalopatia
multifocal progressiva (LEMP) em pacientes com aids no Brasil. Os
objetivos do presente estudo foram descrever as principais
características dos pacientes com LEMP e estimar a freqüência desta
doença em pacientes com aids e doenças oportunistas do sistema
nervoso central (SNC) internados em um centro de referência de São
Paulo, Brasil. Neste estudo retrospectivo e descritivo, identificamos
12 (6%) casos de LEMP entre 219 pacientes com doenças neurológicas
oportunistas do SNC. A idade média dos pacientes com LEMP foi 36
anos e 9 (75%) eram do sexo masculino. As manifestações clínicas
mais freqüentes foram: déficits focais (75%), alterações da fala (58%),
alterações visuais (42%), alterações cognitivas (42%), e problemas de
coordenação (42%). A média da contagem de células T-CD4+ foi 45
células/µL. Oito (67%) dos 12 pacientes com LEMP tiveram diagnóstico
confirmado laboratorialmente e em quatro (33%) casos o diagnóstico
foi possível. Onze (92%) pacientes apresentaram LEMP clássica e um
caso teve LEMP associada à síndrome de reconstituição imune. Em
quatro (33%) pacientes, a LEMP foi a primeira doença definidora de
aids. Durante a internação, três pacientes (25%) faleceram devido a
pneumonia hospitalar e nove (75%) tiveram alta. A LEMP foi apenas
ultrapassada em freqüência pela toxoplasmose cerebral, a
meningoencefalite criptococócica e a neurotuberculose, as três mais
freqüentes doenças neurológicas oportunistas no Brasil. Os resultados
deste estudo sugerem que a LEMP não é uma complicação neurológica
incomum em pacientes com infecção pelo HIV no nosso meio.
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